A Fas agonist induces high levels of apoptosis in haematological malignancies

被引：35
作者：
Greaney, P
Nahimana, A
Lagopoulos, L
Etter, AL
Aubry, D
Attinger, A
Beltraminelli, N
Huni, B
Bassi, I
Sordat, B
Demotz, S
Dupuis, M
Duchosal, MA
机构：
[1] Univ Lausanne Hosp, CHU Vaudois, Serv Hematol, CH-1011 Lausanne, Switzerland
[2] Apoxis SA, CH-1004 Lausanne, Switzerland
来源：
LEUKEMIA RESEARCH | 2006年 / 30卷 / 04期
关键词：
apoptosis; cytotoxicity; Fas; haematological malignancies; cancer;
D O I：
10.1016/j.leukres.2005.08.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We developed and tested a potent hexameric Fas agonist, termed MegaFasL, for its cytotoxic effects on a panel of human haematopoietic malignant cells and healthy human haematopoietic progenitor cells (CD34+CD38low). Results demonstrated that MegaFasL induced apoptosis in cell lines and primary cells representing multiple myeloma (MM), acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) and Burkitt's lymphoma. Cells from a chronic myeloid leukaemia (CML) line and from patients with chronic lymphocytic leukaemia (CLL) were resistant. Furthermore, CD34+CD38low progenitor cells were also resistant to MegaFasL. The data indicate that MegaFasL could be a highly efficient therapeutic agent ex vivo or potentially in vivo. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：415 / 426
页数：12
相关论文
共 49 条
[1]   Single versus double autologous stem-cell transplantation for multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Facon, T ;
Guilhot, F ;
Doyen, C ;
Fuzibet, JG ;
Monconduit, M ;
Hulin, C ;
Caillot, D ;
Bouabdallah, R ;
Voillat, L ;
Sotto, JJ ;
Grosbois, B ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502
[2]   Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Vesole, DH ;
Naucke, S ;
Cheson, B ;
Mattox, S ;
Bracy, D ;
Salmon, S ;
Jacobson, J ;
Crowley, J ;
Tricot, G .
BLOOD, 1997, 89 (03) :789-793
[3]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[4]   CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells [J].
Buhmann, R ;
Nolte, A ;
Westhaus, D ;
Emmerich, B ;
Hallek, M .
BLOOD, 1999, 93 (06) :1992-2002
[5]   Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis [J].
Contri, A ;
Brunati, AM ;
Trentin, L ;
Cabrelle, A ;
Miorin, M ;
Cesaro, L ;
Pinna, LA ;
Zambello, R ;
Semenzato, G ;
Donella-Deana, A .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :369-378
[6]   Drug resistance does not correlate with resistance to Fas-mediated apoptosis [J].
Cullen, KV ;
Davey, RA ;
Davey, MW .
LEUKEMIA RESEARCH, 2001, 25 (01) :69-75
[7]  
de Vries EGE, 2003, DRUGS TODAY, V39, P95
[8]   Death receptors in chemotherapy and cancer [J].
Debatin, KM ;
Krammer, PH .
ONCOGENE, 2004, 23 (16) :2950-2966
[9]   GENETIC MARKING SHOWS THAT PH(+) CELLS PRESENT IN AUTOLOGOUS TRANSPLANTS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) CONTRIBUTE TO RELAPSE AFTER AUTOLOGOUS BONE-MARROW IN CML [J].
DEISSEROTH, AB ;
ZU, ZF ;
CLAXTON, D ;
HANANIA, EG ;
FU, SQ ;
ELLERSON, D ;
GOLDBERG, L ;
THOMAS, M ;
JANICEK, K ;
ANDERSON, WF ;
HESTER, J ;
KORBLING, M ;
DURETT, A ;
MOEN, R ;
BERENSON, R ;
HEIMFELD, S ;
HAMER, J ;
CALVERT, L ;
TIBBITS, P ;
TALPAZ, M ;
KANTARJIAN, H ;
CHAMPLIN, R ;
READING, C .
BLOOD, 1994, 83 (10) :3068-3076
[10]  
Dick JE, 1997, STEM CELLS, V15, P204
12345